Internet Hospital KOL Scripts: Medical-Legal Approval Before the Livestream Goes Live

Life Sciences & Healthcare Blog · Legal cluster

A healthcare livestream is not a chat with a doctor; it is a regulated advertising event, a medical-advice channel, and a platform-distribution pipeline compressed into one live hour. In China, script approval is not optional bureaucracy — it is the only pre-event control that keeps an internet hospital, its physicians, and its commercial partners out of an enforcement file. This article sets out the three legal hats every livestream wears, the statutory gates that apply before the camera starts, and the operational checklist that turns script review from a compliance ritual into a real defence.

Why this matters: the commercial exposure in the live hour#

Internet hospitals and their pharma-adjacent marketing teams are pouring traffic into livestreams because live engagement converts. A single broadcast featuring a credentialed physician can reach tens of thousands of viewers, generate appointment inquiries, and move prescription-adjacent products in a way that static banner advertising never could. That commercial power is precisely what regulators examine. Since 2021, market-supervision authorities have run successive special campaigns targeting illegal healthcare promotion on short-video and livestream platforms, with penalties applied to hospitals, MCN agencies, and individual physicians alike.

The exposure is not hypothetical. Unscripted remarks during a live broadcast — a physician describing a drug as "the fastest cure on the market," a host promising recovery rates, an offhand endorsement of a supplement — are captured, clipped, and reposted by viewers. Enforcement teams work from those clips. Once a clip circulates, the hospital cannot unring the bell: the advertisement has been published, the medical advice has been given, and the platform has distributed it.

Governing legal framework: three statutes, three hats#

The Advertising Law of the People's Republic of China (2015, amended 2021)#

Medical treatment, pharmaceutical, and medical device advertising is one of the most tightly regulated advertising categories in China. Article 16 prohibits content that asserts or guarantees efficacy or safety, and Article 46 imposes a pre-publication examination requirement for medical and pharmaceutical advertisements:

Article 46: Advertisements for medical treatment, drugs, medical devices, health foods, and other advertisements that laws and administrative regulations require to be examined shall be subject to examination of the advertisement content by the relevant department before publication; without examination, they shall not be published.

A doctor speaking on camera about a product's effects is, in substance, medical advertising. If the script asserts efficacy, safety, or superiority, it is running straight into Article 16 territory. If the promotion concerns a drug, medical device, or treatment service, the advertisement content itself requires prior examination regardless of the medium.

Administrative Measures for Internet Diagnosis and Treatment (Trial Implementation) (2018)#

Internet diagnosis and treatment activities are governed by the trial measures issued jointly by the National Health Commission and the National Administration of Traditional Chinese Medicine. Article 23 of the measures addresses the conduct of physicians providing services through internet diagnosis and treatment platforms, requiring that such services be provided within the scope of the physician's registration and in accordance with the platform's diagnosis and treatment procedures. The physician on camera is therefore not merely a guest speaker; the physician is a licensed professional whose online conduct is regulated by health-administration rules that sit alongside advertising law.

Interim Measures for Internet Advertising (2016)#

Internet advertising must be clearly identifiable as advertising, and livestreams that promote products or services are internet advertisements for these purposes. The interim measures require advertising content published through internet channels to comply with the Advertising Law, and they impose platform-side obligations to stop illegal advertising content from being distributed. In a healthcare livestream, the platform is not a neutral conduit; it is a publisher with its own review and take-down duties.

Enforcement context: the SAMR special campaigns and what they produced#

The State Administration for Market Regulation (SAMR) and its provincial bureaus have treated illegal healthcare promotion on livestream and short-video platforms as a priority enforcement target. Across the 2021-2025 period, successive special campaigns — including the "Iron Fist" (tie quan) series and dedicated actions against illegal medical advertising — produced administrative penalties against internet hospitals, pharmaceutical companies, and MCN agencies for broadcasting unapproved medical advertising, using physician credentials to endorse products without examination, and making unsubstantiated efficacy claims in live sessions.

Three enforcement themes recur in the published penalty decisions. First, advertising that should have been pre-examined but was not. Second, physician endorsements that crossed from professional education into product promotion without compliance controls. Third, content that survived because script approval was absent or advisory — the host ad-libbed, the physician improvised, and the compliance department only reviewed the recording afterwards, at which point the violation was already public.

The regulatory trend is toward treating the livestream as a structured advertising event with defined pre-event gates, not as an informal conversation that can be reviewed after the fact. Penalty amounts for illegal medical advertising are calculated under the Advertising Law's penalty provisions, which for serious violations allow fines up to ten times the advertising fees or a statutory cap, alongside confiscation of illegal gains — and repeat offenders face aggravated treatment. The platform side is regulated with equal intensity. Livestream platforms that carry healthcare content are treated as internet-advertising publishers under the Interim Measures for Internet Advertising, which impose duties to verify advertiser qualifications, review advertising content, and take down illegal content when notified. In practice, platforms have responded by adding their own medical-content review pipelines and by referring suspicious livestreams to regulators. A hospital that broadcasts an approved script can still find its stream suspended by a platform that applies a stricter standard — and the compliance team should plan for platform-level review as a parallel gate, not an afterthought. The practical consequence is that script approval must satisfy two reviewers at once: the hospital's own legal and compliance function under the Advertising Law and health-administration rules, and the platform's content-policy gate, which is often more conservative than the statutory floor.

Operational vulnerabilities: where the live hour actually fails#

The gap between the approval deck and the broadcast is where liability is born. The most common failure modes observed across enforcement files include:

• Product claims that exceed the approved label: any statement about indications, dosage, efficacy, or safety that cannot be traced to the approved labelling is an unapproved claim, even if delivered conversationally.
• Guarantee-of-cure language: promises of recovery rates, "100% effective" formulations, or assurances that a treatment will resolve a condition within a set period are textbook Advertising Law Article 16 violations.
• Prescription-drug consumer push: directing viewers to purchase prescription-only medicines without a lawful prescribing path converts a medical conversation into illegal drug promotion; the absence of a valid physician-patient relationship on a compliant platform does not cure the problem, it aggravates it.
• Credential ambiguity: the physician's real name, registration institution, and internet-hospital affiliation must be displayed accurately; an implied affiliation with the hospital that does not exist on paper creates both advertising-law and health-administration exposure.
• Ad-lib risk: the single most dangerous moment in any healthcare livestream is the unscripted question. A viewer asks about a competitor, a side effect, or an off-label use, and the physician answers from professional instinct rather than the approved script. That answer is now published advertising content.

Each of these failure modes has a common root cause: the script was approved as a document but not enforced as a boundary. The physician and the host were never told, in operational terms, which sentences were fixed and which were open.

Advertising-review files from Shanghai#

In my pharmaceutical-compliance and labeling practice in Shanghai, the livestream-KOL request usually lands with the marketing deck already drafted — the claims, the physician, the script and the live date are set, and the compliance review is being asked to bless the package. The regulatory frame is unforgiving: medical and pharmaceutical advertising is one of the most tightly regulated categories in China, with the Advertising Law’s prohibition on efficacy guarantees, the pre-publication examination requirement, and the internet-advertising rules that treat a livestream promoting products as advertising regardless of format. The gap between the approval deck and the broadcast is where liability is born: the claim that exceeds the approved label, the guarantee-of-cure language delivered conversationally, the prescription-adjacent mention that turns the live hour into an unapproved promotion. The SAMR special campaigns across 2021-2025 made the enforcement posture clear — internet hospitals and their marketing partners are a priority target, and the penalty files show that the platform’s own review does not protect the hospital. My advice is to build the script-approval system as a real gate, not a signature exercise: every product claim matched against the approved label and the examination document, the prescription boundary reviewed before the broadcast, and the compliance reviewer sitting with the production team so the deck that is approved is the deck that is broadcast. The live hour is the commercial exposure; the script file is the defence.

Strategic compliance roadmap: a script-approval system that works#

A defensible script-approval process has five gates, and each gate must be completed before the livestream goes live:

1. Medical-claims gate: every product claim, indication, and comparative statement in the script is matched against the approved label and the approved advertisement examination document; any claim without a traceable source is deleted or reworded.
2. Prescription gate: the script is reviewed for any consumer-facing push of prescription drugs; if the broadcast cannot rely on a lawful prescription pathway, the prescription-drug content is removed entirely.
3. Credential gate: the physician's name, registration institution, and internet-hospital affiliation are verified and the on-screen disclosure language is locked into the script.
4. Ad-lib protocol gate: the script defines a fixed core (opening, approved talking points, closing) and an open Q-and-A zone governed by rules — no competitor comparisons, no off-label claims, no unapproved efficacy statements, no guarantees; hosts and physicians are trained on the boundary in writing.
5. Contract and evidence gate: the commercial agreement with the host and the physician allocates responsibility for ad-lib content, requires recording retention for the statutory period, and grants the hospital take-down and correction rights that can be exercised within hours, not weeks.

After the broadcast, the recorded file is the evidence file. Retain it, index the approved script against it, and conduct a post-event reconciliation: every deviation is logged, corrected, and — where the deviation crossed a legal line — reported internally and, where required, to the platform for take-down before clips propagate.

The approval process should also cover the physician's own professional risk. A physician who appears in a healthcare livestream is on camera both as a professional and as a person, and the script that protects the hospital does not automatically protect the physician's licence. The engagement agreement should therefore state the physician's right to review the final script, the prohibition on reading unapproved content, and the hospital's obligation to support the physician in a regulatory inquiry arising from the hospital's own production decisions. Physicians who understand that the script is their shield — not their constraint — are more likely to stay on script, and the file shows the hospital built that understanding into the engagement rather than assuming it.

What not to do#

Do not treat script approval as a signature exercise. Do not allow the compliance reviewer to sit in a different city from the production team, reviewing a deck that no longer resembles what will be broadcast. Do not rely on the platform's own review — platform moderation protects the platform, not the hospital. And do not assume that a physician's medical licence immunises promotional content; the licence authorises diagnosis and treatment, not advertising claims.

The script-approval programme should also be reviewed periodically — after each new product launch, each new physician engagement, and each regulator campaign — so that the checklist reflects the current rules and the current product line, not the deck from last year's broadcast season.

Read next: Internet hospital compliance · Pharma advertising · Device advertising

Cluster: Life sciences legal hub · Life sciences blog